[1] TER TELGTE A，VAN LEIJSEN E M C，

WIEGERTJES K，et al. Cerebral small vessel disease：

from a focal to a global perspective[J]. Nat Rev

Neurol，2018，14（7）：387-398.

[2] WISEMAN S J，BASTIN M E，JARDINE C L，et

al. Cerebral small vessel disease burden is increased

in systemic lupus erythematosus[J]. Stroke，2016，47

（11）：2722-2728.

[3] WARDLAW J M，SMITH E E，BIESSELS G J，et

al. Neuroimaging standards for research into small

vessel disease and its contribution to ageing and

neurodegeneration[J]. Lancet Neurol，2013，12（8）：

822-838.

[4] LYNCH D S，WADE C，PAIVA A R B，et al.

Practical approach to the diagnosis of adult-onset

leukodystrophies：an updated guide in the genomic

era[J]. J Neurol Neurosurg Psychiatry，2019，90（5）：

543-554.

[5] WARDLAW J M，SMITH C，DICHGANS M.

Mechanisms of sporadic cerebral small vessel disease：

insights from neuroimaging[J]. Lancet Neurol，2013，

12（5）：483-497.

[6] IHARA M，YAMAMOTO Y. Emerging evidence

for pathogenesis of sporadic cerebral small vessel

disease[J]. Stroke，2016，47（2）：554-560.

[7] URBANSKI G，YELNIK C M，MAILLARD H，et

al. Antiphospholipid syndrome with isolated isotype

M anticardiolipin and/or anti-B2GPI antibody is

associated with stroke[J]. Stroke，2018，49（11）：2770-2772.

[8] LUCCHESE G，FLOEL A，STAHL B. Crossreactivity

as a mechanism linking infections to

stroke[J]. Front Neurol，2019，10：469.

[9] AARABI G，THOMALLA G，HEYDECKE G，et

al. Chronic oral infection：an emerging risk factor of

cerebral small vessel disease[J]. Oral Dis，2019，25

（3）：710-719.

[10] BOEHME A K，MCCLURE L A，ZHANG Y，et al.

Inflammatory markers and outcomes after lacunar

stroke：levels of inflammatory markers in treatment

of stroke study[J]. Stroke，2016，47（3）：659-667.